IRVING, Texas, Jan 26, 2007 /PRNewswire-FirstCall via COMTEX/ -- Carrington Laboratories, Inc., (CARN) today announced the Company and Mannatech, Incorporated (MTEX) have signed a multi-million dollar trademark license and supply agreement. Under the non-exclusive agreement, Carrington will supply its trademarked ingredient Manapol(R) powder to Mannatech for a period of up to three (3) years for use in its glyconutrient and nutritional supplements. Manapol(R) powder is an original ingredient in Mannatech's flagship product, Ambrotose(R), and from 1994 to 2005, Carrington and Mannatech had a supply agreement in place.
Sam Caster, Chairman and Chief Executive Officer of Mannatech, stated, "This supply agreement helps secure an uninterrupted source of Manapol(R), thus ensuring that we continue to meet the growing associate demand for our patented glyconutrient products."
Manapol(R) powder is regulated as a dietary supplement ingredient and contains a unique composition of calcium, fiber, pectin and acetylated mannans. There is no other product from Aloe vera L. that preserves this natural structure. Thus, no other aloe-based product has the bioactive profile of Manapol(R) needed for both immune modulating benefits and the DSHEA claim of immune enhancing. Manapol(R) is used in a variety of dietary supplements and can be formulated in capsules, tablets, liquids, powder blends and power bars. Manapol(R) is a registered trademark of Carrington Laboratories and is recognized by regulatory agencies in the United States, Japan and other countries as a patented, product by process from Aloe vera L. It is produced in an ISO-certified facility and under cGMP for drug products using a precipitation process with medicinal-grade ethanol. The ethanol process is key to preserving the consistency and bioactivity of Manapol(R) powder and works by denaturing naturally-occurring enzymes that destroy the polymer structure over time, absorbing the anthraquinones (a laxative component) and sterilizing the product. Manapol(R) is never subjected to heat, enzymes or charcoal filtration during its production, resulting in a product rich in polymeric polysaccharides preserved in their freshest and most bio- active state.
Mannatech, Incorporated is a global wellness solutions provider that develops innovative, high-quality, proprietary nutritional supplements, topical and skin care products, and weight management products that are sold through approximately 536,000 independent Associates and Members located in the United States and the international markets of Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark and Germany.
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. DelSite Biotechnologies, a subsidiary of Carrington, is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. The GelVac(TM) formulation of GelSite is being funded by HHS and is being developed as a nasal powder delivery system for vaccines and therapeutics in particular the H5N1 Avian (Bird) Flu. Research on Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed November 14, 2006.